Radiance's new catheter designs in BRITE trials:
This article was originally published in Clinica
Executive Summary
Radiance Medical Systems has gained permission from the US FDA to use new catheter designs of its monorail RDX coronary radiation delivery system in its BRITE II and BRITE-SVG in-stent restenosis studies (see Clinica No 942, p 22). The Irvine, California company says it has enhanced the materials and design features of the RDX to provide a lower profile, more flexible device, with a longer shelf-life. An over-the-wire version of the RDX catheter has also been approved for use in both trials.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.